Table 1 Characteristics of patients with Acinetobacter spp. bloodstream infection, stratified by outcome

Male sex

22 (55.0)

14 (53.8)

8 (57.1)

0.842

Age

median (range)

25.5 (1–62)

18.5 (7–40)

31 (17–49)

0.243

≥ 45

11 (27.5)

6 (23.1)

5 (35.7)

0.469

Underlying diseases

VSAA

9 (22.5)

3 (11.5)

6 (42.9)

0.044*

ALL

11 (27.5)

10 (38.5)

1 (7.1)

0.061

AML

17 (42.5)

10 (38.5)

7 (50.0)

0.481

MDS

2 (5.0)

2 (7.7)

0 (0.0)

0.533

DLBCL

1 (2.5)

1 (3.8)

0 (0.0)

1.000

Diabetes

3 (7.5)

2 (7.7)

1 (7.1)

1.000

Carbapenem-resistantAcinetobacterspp. colonization

10 (25.0)

6 (23.1)

4 (28.6)

0.718

Total length of hospital stay

35 (23–59)

35 (25–58)

35 (22–69)

0.790

Length of hospital stay before BSI

15 (5–24)

12 (5–19)

21 (8–36)

0.118

Accompanying symptoms

Fever

40 (100.0)

26 (100.0)

14 (100.0)

Oral mucositis or pharyngitis

11 (27.5)

6 (23.1)

5 (35.7)

0.469

Sinus infection

2 (5.0)

1 (3.8)

1 (7.1)

1.000

Pneumonia

22 (55.0)

12 (46.2)

10 (71.4)

0.125

Pleural effusion

12 (30.0)

5 (19.2)

7 (50.0)

0.071

Intracranial infection

5 (12.5)

0 (0.0)

5 (35.7)

0.003*

Skin or soft tissue infection

4 (10.0)

1 (3.8)

3 (21.4)

0.115

Urinary tract or perineal infection

0 (0.0)

0 (0.0)

0 (0.0)

Perianal infection

6 (15.0)

4 (15.4)

2 (14.3)

1.000

Respiratory failure

9 (22.5)

1 (3.8)

8 (57.1)

< 0.001*

Cardiac dysfunction

13 (32.5)

5 (19.2)

8 (57.1)

0.031*

0.776 (0.068–8.912)

0.838

Severe sepsis or septic shock

10 (25.0)

1 (3.8)

9 (64.3)

< 0.001*

Laboratory results

Neutropenia at the onset of BSI

31 (77.5)

17 (65.4)

14 (100.0)

0.016*

Unresolved neutropenia before infection

13 (35.1) ^a

6 (24.0) ^a

7 (58.3) ^a

0.067

Unresolved neutropenia after infection

21 (52.5)

8 (30.8)

13 (92.9)

0.001*

Hypoproteinemia

19 (48.7) ^b

10 (40.0) ^b

9 (64.3) ^b

0.146

PCT (ug/L)

0.81 (0.11–2.33)

0.14 (0.10–1.10)

1.79 (0.53–21.60)

0.025*

CRP (mg/L)

37.16 (11.07-117.41)

12.40 (9.32–58.30)

128.13 (61.00-243.78)

0.001*

Antibiotic use

Previous antibiotic use

34 (85.0)

21 (80.8)

13 (92.9)

0.399

Antimicrobial exposure at the onset of BSI

21 (52.5)

12 (46.2)

9 (64.3)

0.273

Inappropriate empirical therapy

12 (30.0)

4 (15.4)

8 (57.1)

0.011*

11.234 (1.261–20.086)

0.030*

Definitive combination therapy

21 (52.5)

13 (50.0)

8 (57.1)

0.666

Antifungal agents in combination

28 (70.0)

17 (65.4)

11 (78.6)

0.484

Time of antibiotic treatment after BSI

14 (6–25)

16 (8–32)

5 (4–13)

0.006*

Resistance profiles

Carbapenem-resistant

16 (40.0)

9 (34.6)

7 (50.0)

0.343

Multidrug-resistant

19 (47.5)

11 (42.3)

8 (57.1)

0.370

Extensively drug-resistant

5 (12.5)

1 (3.8)

4 (28.6)

0.043*

Tetracycline-resistant

8 (25.8) ^c

3 (13.6) ^c

5 (55.6) ^c

0.027*

3.568 (0.341–37.313)

0.288

Broad-spectrum cephalosporins-resistant

37 (92.5)

24 (92.3)

13 (92.9)

1.000

Fluoroquinolones-resistant

13 (32.5) ^d

7 (28.0) ^d

6 (42.9) ^d

0.482

Aminoglycosides-resistant

14 (35.0)

7 (26.9)

7 (50.0)

0.178